SiBionics and PharmaSens Showcase Niia Signature

MILAN, Saturday, Oct. 3, 2026. At the European Association for the Study of Diabetes 2026 conference, medical technology firms SiBionics and PharmaSens detailed their ongoing collaboration on automated insulin delivery hardware. According to a report by PR Newswire M&A published via PR Newswire, the companies featured the development milestones of niia signature, an investigational device that pairs continuous glucose monitoring with insulin delivery.

The presentation formed part of a broader corporate exhibition structured around three chapters titled See More: Beyond Glucose, Act Earlier: From Insight to Intervention, and Go Further: Realizing the Unimagined. These segments covered multi-parameter monitoring, multimodal sensing, and prospective biosensing applications. The companies also hosted an industry symposium chaired by Prof. Mark Evans of the University of Cambridge and Cambridge University Hospitals, along with Dr. Guido Freckmann of the Institute for Diabetes-Technology GmbH in Germany.

Clinical Insights and SMART02 Feasibility Data

During the symposium, clinical researchers presented data on continuous glucose monitoring and integrated management systems. Prof. Karolina Kędzierska-Kapuza discussed individualized care for type 3c diabetes, while Prof. Wei Qiang shared accuracy findings and future multimodal sensing concepts. Prof. Andrej Janež spoke on continuous ketone monitoring within the GLP-1 era, and Prof. Ahmad Haidar presented ketone monitoring research alongside the first findings from the SMART02 feasibility study.

The SMART02 study evaluated an early prototype of niia signature, which combines a continuous glucose monitor, an insulin delivery mechanism, and an automated glucose control algorithm into a single wearable patch. The joint development between PharmaSens and SiBionics began after the two medtech entities announced their partnership in June 2025. The investigational system is designed to alleviate the daily management burdens associated with wearing separate apparatuses for automated insulin delivery.

Addressing Technical Integration Challenges

The clinical evaluation examined a primary technical obstacle in patch design: maintaining sensor measurement accuracy when insulin is infused directly adjacent to the sensing site. Investigators observed that temporary signal interference following an insulin bolus was uncommon overall. However, interference occurred with a probability of 20 to 25% during bolus doses of 10 units or more. Across the study cohort, the sensor signal typically recovered within approximately 20 minutes following bolus delivery.

In the subsequent phase of the evaluation, the hardware prototype operated alongside the automated glucose control algorithm developed by Prof. Ahmad Haidar. Study results showed consistent performance across the PharmaSens patch pump, the SiBionics sensor component, and the control algorithm. The companies exhibited these findings at the main conference booth to mark an early developmental milestone for the partnership.

Corporate Backgrounds of the Partner Firms

Despite the exhibition milestones, niia signature remains an investigational device that lacks regulatory approval or commercial clearance in any global market. Founded in 2015 and headquartered in Shenzhen, SiBionics employs nearly 700 professionals worldwide. The medical technology enterprise specializes in continuous glucose monitoring and multi-parameter health solutions, operating an in-house multidisciplinary research and development team focused on biosensing, chip design, materials science, and artificial intelligence.

Co-developer PharmaSens AG is a privately owned Swiss enterprise focused on simplifying diabetes care and expanding the adoption of insulin pump therapy. The Swiss firm brings engineering experience spanning multiple generations of commercial insulin pumps, backed by a patented international portfolio of medical devices. Both companies maintain that further clinical investigation remains necessary to establish the operational performance and broader therapeutic potential of the integrated patch system.